Overview

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

Status:
Not yet recruiting
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drugs listed below are approved by the U.S. Food and Drug Administration (FDA) but are being used "off-label" in this study. This means that the drugs are not currently approved to treat TBI.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
United States Department of Defense
Treatments:
Atorvastatin
Calcium
Candesartan
Candesartan cilexetil
Minocycline